CTOs on the Move

Lumen Bioscience Inc

www.lumenbioscience.com

 
We are a team of inspired individuals, driven by love of science, commitment to collaboration, and relentless pursuit of excellence. Lumen`s technology allows it to create clever new high-value products in spirulina (Arthrospira platens), a type of blue-green algae.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Lumen Bioscience Inc raised $11.2M on 12/05/2017

Similar Companies

Synchem

Synchem is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meissa Vaccines

Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens.

STAT PHARMACEUTICALS

STAT PHARMACEUTICALS is a Santee, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pillar Biosciences

Pillar Biosciences aims to "Make precision medicine the first option for every patient" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today`s high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%. Current as of May 25, 2021.